

Case 9 参考文献

1. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings : a scientific statement from the American Heart Association and the American College of Cardiology Foundation. *Circulation* 2010 ; 121 : 1047-60. **PMID** : 20142454
2. Boubes K, Batlle D, Tang T, et al. Serum potassium changes during hypothermia and rewarming : a case series and hypothesis on the mechanism. *Clin Kidney J* 2022 ; 16 : 827-34. **PMID** : 37151414
3. Nakatani K, Nakagami-Yamaguchi E, Shinoda Y, et al. Improving the safety of high-concentration potassium chloride injection. *BMJ Open Qual* 2019 ; 8 : e000666. **PMID** : 31259289
4. Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia : a clinical update. *Endocr Connect* 2018 ; 7 : R135-46. **PMID** : 29540487
5. Yalamanchili HB, Calp-Inal S, Zhou XJ, et al. Hypokalemic nephropathy. *Kidney Int Rep* 2018 ; 3 : 1482-8. **PMID** : 30450476
6. Palmer BF, Clegg DJ. The use of selected urine chemistries in the diagnosis of kidney disorders. *Clin J Am Soc Nephrol* 2019 ; 14 : 306-16. **PMID** : 30626576
7. Grams ME, Hoenig MP, Hoorn EJ. Evaluation of hypokalemia. *JAMA* 2021 ; 325 : 1216-7. **PMID** : 33755054
8. Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. *Adv Physiol Educ* 2016 ; 40 : 480-90. **PMID** : 27756725
9. 五島隆宏, 植西憲達. 代謝性アシドーシスの存在がわかった。では、その原因は？—アニオンギャップ非開大型代謝性アシドーシス. *Intensivist* 2025 ; 17 : 69-80.
10. Johnson RJ, Feehally J, Floege J, et al. *Comprehensive clinical nephrology*. 6th ed. Edinburgh : Elsevier, 2018.
11. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. *Nat Rev Nephrol* 2011 ; 7 : 189-200. **PMID** : 21364518
12. Gilbert SF, Weiner DE, National Kidney Foundation. (eds) *National Kidney Foundation primer in kidney diseases*. 8th ed. Philadelphia : Elsevier, 2022.
13. Zhang X, Yuan Y. Effect of replacement therapy (CRRT) and hemodialysis (IHD) on severe acute renal failure. *Front Pharmacol* 2023 ; 14 : 1122778. **PMID** : 37547338

14. Singla M, Gupta A. An overlooked cause of polyuria. *Am J Med* 2019 ; 132 : e33-4. **PMID** : 30691554
15. Vermue IM, Begum R, Castilho M, et al. Renal biology driven macro-and microscale design strategies for creating an artificial proximal tubule using fiber-based technologies. *ACS Biomater Sci Eng* 2021 ; 7 : 4679-93. **PMID** : 34490771
16. Soleimani M, Rastegar A. Pathophysiology of renal tubular acidosis : core curriculum 2016. *Am J Kidney Dis* 2016 ; 68 : 488-98. **PMID** : 27188519
17. Rennke H, Denker BM. Renal pathophysiology : the essentials. 6th ed. Philadelphia : Wolters Kluwer Health, 2024.
18. Haque SK, Ariceta G, Batlle D. Proximal renal tubular acidosis : a not so rare disorder of multiple etiologies. *Nephrol Dial Transplant* 2012;27:4273-87. **PMID**:23235953
19. Kashoor I, Batlle D. Proximal renal tubular acidosis with and without Fanconi syndrome. *Kidney Res Clin Pract* 2019 ; 38 : 267-81. **PMID** : 31474092
20. Kalantri P, Lomashvili K. Deruxtecán-induced reversible Fanconi syndrome. *Cureus* 2023 ; 15 : e40890. **PMID** : 37492824
21. Portales-Castillo I, Mount DB, Nigwekar SU, et al. Zoledronic acid-associated Fanconi syndrome in patients with cancer. *Am J Kidney Dis* 2022;80:555-9. **PMID** : 35219759
22. Wu Y, Ma T, Yu X, et al. Severe hypophosphatemia as the initial presentation of renal Fanconi's syndrome and distal renal tubular acidosis related to zoledronic acid : a case report and literature review. *Kidney Blood Press Res* 2023 ; 48 : 18-27. **PMID** : 36412607
23. Yoshinami T, Yagi T, Sakai D, et al. A case of acquired Fanconi syndrome induced by zoledronic acid. *Intern Med* 2011 ; 50 : 1075-9. **PMID** : 21532237
24. Katsunuma R, Mitsumoto K, Mizumoto A, et al. Fanconi syndrome associated with long-term treatment with zoledronate. *Intern Med* 2023 ; 62 : 2103-5. **PMID** : 36450467
25. Oliveira M, Santos MT, Costa A. Fanconi syndrome related to zoledronic acid. *Port J Nephrol Hypert* 2019 ; 33 : 184-7.
26. Saito F, Osaku T, Sato G, et al. Drug-induced Fanconi syndrome in a patient with breast cancer : a case report. *Toho J Med* 2018 ; 4 : 146-51.
27. Torimoto K, Okada Y, Arao T, et al. A case of zoledronate-induced tubulointerstitial nephritis with Fanconi syndrome. *Endocr J* 2012 ; 59 : 1051-6. **PMID** : 22814143

28. Gutiérrez Sánchez MJ, Petkov Stoyanov V, Pedraza Cezón L, et al. Kidney failure caused by tubular interstitial nephropathy with Fanconi syndrome after treatment with zoledronic acid. *Nefrologia* 2017 ; 37 : 660-1. **PMID** : 29122217
29. Okagawa Y, Sato Y, Onuma H, et al. A case of Fanconi syndrome induced by zoledronic acid in a metastatic colorectal cancer patient. *Jpn J Cancer Chemother* 2015 ; 42 : 867-70.
30. de Roij van Zuijdewijn C, van Dorp W, Florquin S, et al. Bisphosphonate nephropathy : a case series and review of the literature. *Br J Clin Pharmacol* 2021 ; 87 : 3485-91. **PMID** : 33595131
31. Drake MT, Clarke BL, Khosla S. Bisphosphonates : mechanism of action and role in clinical practice. *Mayo Clin Proc* 2008 ; 83 : 1032-45. **PMID** : 18775204
32. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. *Kidney Int* 2008 ; 74 : 1385-93. **PMID** : 18685574